Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + figitumumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The combination of carboplatin + paclitaxel is a well-established chemotherapy regimen used to treat various solid tumors including ovarian, lung, and breast cancer. Carboplatin and paclitaxel work through different mechanisms; paclitaxel should be given before carboplatin because if carboplatin is administered first, it can inhibit paclitaxel's cytotoxic effects on cancer cells, specifically interfering with paclitaxel-induced IkappaBalpha degradation and bcl-2 phosphorylation. The optimal schedule is sequential exposure of paclitaxel followed by carboplatin. Figitumumab is an investigational monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R). The provided search results do not specifically mention figitumumab in combination with carboplatin and paclitaxel, and therefore, detailed information about its specific role or established clinical applications within this triple combination is not available.
- Other names
- figitumumab + carboplatin + paclitaxel
02
Targets
MicrotubuleDNAIGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on carboplatin + figitumumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + figitumumab + paclitaxel.